[-] Show simple item record

dc.contributor.authorMisra, Shamitaeng
dc.contributor.authorStevermer, James J.eng
dc.contributor.authorEwigman, Bernardeng
dc.contributor.otherFamily Physicians Inquiries Networkeng
dc.date.issued2009eng
dc.description.abstractAvoid prescribing an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) for patients at high risk of vascular events or renal dysfunction. The combination does not reduce poor outcomes, and leads to more adverse drug-related events than an ACE inhibitor or ARB alone. Stength of recommendation: B: 1 large, high-quality randomized controlled trial (RCT).eng
dc.identifier.urihttp://hdl.handle.net/10355/5429
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionPriority Updates to Research Literature (PURLs) (2009)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 58, no. 01 (January 2009): 24+.eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subject.lcshAngiotensin converting enzyme -- Side effectseng
dc.subject.lcshAngiotensins -- Side effectseng
dc.subject.lcshDrug interactionseng
dc.subject.otherHigh risk patientseng
dc.subject.otherAngiotensin receptor blockereng
dc.subject.otherACE inhibitoreng
dc.titleACE inhibitors and ARBs: One or the other -- not both -- for high-risk patientseng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record